ClinicalTrials.gg
Not yet recruitingNCT07948161Updated Nov 19, 2026

Multisensory Room Therapy for Stress and Sensory Regulation in Children With Autism and Their Caregivers

An interventional study of Multisensory room therapy and Standard behavioural therapy in Autism Spectrum Disorder, Parenting Stress and Sensory Processing Disorder, sponsored by SERGIO MONTERO NAVARRO. Not yet recruiting. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by SERGIO MONTERO NAVARRO · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether therapy in a multisensory room improves sensory processing, behavioural and attentional regulation and stress in children aged 3 to 12 years with autism spectrum disorder (support level 2-3), and whether it reduces stress in their main caregivers. The main question it aims to answer is: does sensory processing (Sensory Profile 2) change more after 8 weeks of multisensory room therapy than after 8 weeks of standard behavioural therapy? Researchers will also compare executive function, attention and behaviour, parental stress, and stress-related biomarkers in saliva (cortisol, oxytocin and inflammatory interleukins). They will also record physiological stress signals in caregivers (heart rate, skin conductance, breathing and temperature).

Sixty children will be randomly assigned to one of two groups. Children in the first group will receive two individual 45-minute multisensory room sessions per week for 8 weeks. Children in the second group will receive standard behavioural therapy with psychology and speech therapy, without multisensory stimulation. Caregivers will complete questionnaires and give saliva samples before and after the 8-week programme.

Read the detailed description

Background. Sensory processing differences are highly prevalent in autism spectrum disorder (ASD) and are associated with anxiety, emotional dysregulation and lower adaptive functioning. Children with ASD show atypical activation of the hypothalamic-pituitary-adrenal axis and elevated pro-inflammatory cytokines. Parents of children with ASD report high parenting stress. Multisensory environments (Snoezelen®) are widely used to support self-regulation, but controlled trials with objective outcomes are scarce.

Design. Randomised, controlled, parallel-group trial with pre-post assessment. Families with a child aged 3-12 years with ASD (support level 2-3) attending the Centre de Teràpia Interfamiliar (Elche, Spain) are randomised 1:1. Randomisation is stratified by age, sex and the primary outcome, in blocks of two, and the sequence is concealed. Outcome assessors are blinded to group allocation; therapists cannot be blinded.

Interventions. Multisensory group: 16 individual 45-minute sessions (2 per week for 8 weeks) in a multisensory room, delivered by occupational therapists trained in multisensory stimulation in ASD. Each session follows a semi-structured protocol: welcome and adaptation (5 min); guided sensory regulation with graded visual, auditory, tactile, vestibular and proprioceptive stimuli (15-20 min); active participation and control of the environment (10-15 min); and closure with return to calm (5 min). Control group: 45-minute sessions of standard behavioural therapy with psychology and speech therapy, under standard lighting, without therapeutic multisensory stimuli and with the same therapist presence.

Assessments. Baseline (T0): child saliva biomarkers; caregiver-reported Sensory Profile 2, BRIEF-P/BRIEF-2, Conners scales and PSI-SF; caregiver saliva and hair biomarkers; and caregiver physiological recording (BIOPAC MP36R). During the intervention (T1): child saliva before and after each session, and a structured observational self-regulation record after each session. After 8 weeks (T2): caregiver-reported scales, caregiver biomarkers and physiological recording. Salivary cortisol, oxytocin, IL-6, IL-1β, IL-17A and TNF-α are analysed by ELISA at Universidad CEU Cardenal Herrera.

Setting and data. The study is conducted at the Centre de Teràpia Interfamiliar (Elche, Spain) in collaboration with the Neurobiology research group of Universidad CEU Cardenal Herrera. Data are pseudonymised and handled in accordance with the GDPR and Spanish Organic Law 3/2018.

02

Conditions studied

  • Autism Spectrum Disorder
  • Parenting Stress
  • Sensory Processing Disorder

Keywords

  • Multisensory environment
  • Snoezelen
  • Salivary cortisol
  • Oxytocin
  • Interleukins
  • Electrodermal activity
  • Executive function
  • Caregivers
  • Children
03

In context

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's planned enrollment of 120 is above the median of 52 across 1,373 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

SERGIO MONTERO NAVARRO is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (children):

  • Clinical diagnosis of autism spectrum disorder, support level 2 or 3 ().
  • Age 3 to 12 years.
  • Attending and registered at the Centre de Teràpia Interfamiliar.
  • Stable therapeutic and pharmacological treatment during the study period.
  • Able to tolerate entering and remaining in the multisensory room.
  • Written from parents or legal guardians.

Exclusion Criteria (children):

  • Uncontrolled epilepsy.
  • Recent changes in medication.
  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the intervention.
  • Persistent refusal of, or inability to adapt to, the multisensory room.

Inclusion Criteria (caregivers):

  • Adult (18 years or older) main caregiver of an enrolled child.
  • Sufficient cognitive capacity to understand the informed consent.

Exclusion Criteria (caregivers):

  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Multisensory room therapy

    Children with ASD receive 8 individual 45-minute sessions (1 per week for 8 weeks) in a multisensory room. Their caregivers complete assessments and provide biological samples.

    Behavioral: Multisensory room therapy

  • Active comparator
    Standard behavioural therapy

    Children with ASD receive 45-minute sessions of standard behavioural therapy (psychology and speech therapy) without multisensory stimulation, over the same 8-week period. Their caregivers complete the same assessments.

    Behavioral: Standard behavioural therapy

Interventions

  • BehavioralMultisensory room therapy

    Semi-structured individual session in a multisensory (Snoezelen®) room delivered by occupational therapists trained in multisensory stimulation in ASD: (1) welcome and adaptation, 5 min, with dim light and no loud sounds; (2) guided sensory regulation, 15-20 min, with graded visual, auditory, tactile, vestibular and proprioceptive stimuli adjusted to the child's profile; (3) active participation and control of the environment, 10-15 min, in which the child chooses or modulates stimuli; (4) closure and return to calm, 5 min. Two sessions per week for 8 weeks.

    Also known as: Snoezelen; Multisensory environment (MSE)

  • BehavioralStandard behavioural therapy

    45-minute session with psychology and speech therapy addressing children with ASD support level 2-3, under standard lighting, without therapeutic multisensory stimuli, and with the same therapist presence as the experimental arm.

06

What researchers measure

Primary outcomes

  1. Change in sensory hyper-reactivity (Sensory Profile 2, Sensitivity quadrant)

    Sensory Profile 2 - Child form, completed by the main caregiver. Raw score of the Sensitivity quadrant (19 items, each rated from 1 = almost never to 5 = almost always; range 19-95). Higher scores indicate more frequent sensory hyper-reactivity (worse outcome).

    Time frame: Baseline and week 8

Secondary outcomes

  1. Change in executive function (Behavior Rating Inventory of Executive Function, BRIEF-P / BRIEF-2)

    Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P, ages 3-5) or BRIEF-2 parent form (ages 5-12), completed by the main caregiver. Global Executive Composite raw score (63 items rated 1-3; range 63-189). Higher scores indicate greater executive dysfunction (worse outcome).

    Time frame: Baseline and week 8

  2. Change in emotional and behavioural problems (SENA, Global Problems Index)

    Child and Adolescent Assessment System (SENA), family-report form for ages 3-6 or 6-12, completed by the main caregiver. Global Problems Index, T-score (normative mean 50, SD 10; range of risk 65-69; significative range of risk: \>70). Higher scores indicate more emotional and behavioural problems (worse outcome).

    Time frame: Baseline and week 8

  3. Parenting stress (PSI-SF)

    PSI-SF is a 36-item, self-report measure of parenting stress. It includes three subscales: Parental Distress (PD; e.g, "I feel trapped by my responsibilities as a parent", "I feel lonely and without friends"), Parent-Child Dysfunctional Interaction (PCDI; e.g, "Sometimes I feel my child doesn't like me and doesn't want to be close to me", "When I do things for my child I get the feeling that my efforts are not appreciated" ), and Difficult Child (DC; e.g, "My child makes more demands on me than most children", "My child gets upset easily over the smallest thing"). Each subscale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree), with subscales scores ranging from 12 to 60. A Total score is calculated by summing the three subscales scores, ranging from 36 to 180. Scores of 90 or above may indicate a clinical level of stress.

    Time frame: Baseline and week 8

  4. Child salivary cortisol (ng/mL)

    ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of cortisol: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

    Time frame: Baseline and before/after each session, weeks 1-8

  5. Child salivary oxytocin (pg/mL)

    ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of oxytocin: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

    Time frame: Baseline and before/after each session, weeks 1-8

  6. Child salivary pro-inflammatory cytokines

    Salivary IL-6, IL-1β, IL-17A and TNF-α (pg/mL, ELISA).

    Time frame: Baseline and before/after each session, weeks 1-8

  7. Caregiver stress biomarkers - Salivary cortisol (ng/mL)

    Time frame: Baseline and week 8

  8. Caregiver stress biomarkers - oxytocin (pg/mL)

    Time frame: Baseline and week 8

  9. Caregiver stress biomarkers - IL-6, IL-1β, IL-17A and TNF-α (pg/mL) (ELISA)

    Time frame: Baseline and week 8

  10. Caregiver stress biomarkers - hair cortisol (pg/mg)

    Time frame: Baseline and week 8

  11. In-session self-regulation (observational record)

    Therapist-rated 8-item record (0-3 per item; total 0-24). Higher scores indicate greater self-regulation difficulty.

    Time frame: After each session, weeks 1-8

  12. Heart rate and heart rate variability (LF, HF, LF/HF ratio). BIOPAC MP36R device

    During a recording of about 30 minutes

    Time frame: Baseline and week 8

  13. Galvanic response by means of Skin conductance (SC). micro-siemens or micro-omhios. BIOPAC MP36R device

    During a recording of about 30 minutes

    Time frame: Baseline and week 8

  14. Breathing rate (breaths per minute). BIOPAC MP36R device

    During a recording of about 30 minutes

    Time frame: Baseline and week 8

  15. Skin temperature (ºC). BIOPAC MP36R device

    During a recording of about 30 minutes

    Time frame: Baseline and week 8

Other outcomes

  1. Adverse events

    Number of children with behavioural crises, sensory overload requiring session interruption, or other adverse events, by group.

    Time frame: Weeks 1-8

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Coded data may be shared only for purposes consistent with the study and under confidentiality guarantees; no international transfers are planned.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2027, 2 months later.

Of 805 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 2 months is below that.

Counting every sponsor, half of 828 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 19, 2026
StartEst.
Jan 3, 2027
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948161
Lead sponsor
SERGIO MONTERO NAVARRO
Collaborators
Centre de Teràpia Interfamiliar (CTI), Elche, Cardenal Herrera University
Responsible party
SERGIO MONTERO NAVARRO (PhD, Lecturer in Physiotherapy, Cardenal Herrera University) — Sponsor-investigator
First posted
Nov 19, 2026
Start date
Jan 3, 2027 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

SERGIO MONTERO-NAVARRO, PhD
Contact
sergio.montero@uchceu.es
+34965426486 ext. 67604

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion